Drug intelligence / Profile preview

GS-9723

Development stage: Discontinued
Lead developer: Gilead Sciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GS-9723 is a human immunoglobulin monoclonal antibody originally developed by Gilead Sciences as a broadly neutralizing antibody targeting the CD4 binding site of the HIV envelope glycoprotein. Its main investigated indication was HIV infection within immune and infectious disease settings. The mechanism of action involves neutralizing HIV by binding critical epitopes needed for viral entry into host cells. Clinical development has been discontinued and no further trials or approvals are ongoing[1][7].

Targets

Env (HIV-1 envelope glycoprotein)

Beyond the preview

Go deeper on GS-9723.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GS-9723.

Explore the full profile